List/Grid Tag Archives: immunotherapy
Stand Up To Cancer and St. Baldrick’s Pediatric Cancer Dream Team Announced
The announcement of the Stand Up to Cancer and St. Baldrick’s pediatric cancer dream team brings great excitement and promise. The $14.5 million dollar grant was announced yesterday and awarded to Dr. J.M. Maris (CHOP) and Dr. C.L. Mackall (NCI) to pursue their work in the area of “Immunogenomics to Create New Therapies for High-Risk Childhood Cancers”.
This work will combine the ...
Dendritic Cell Vaccine for Relapsed Neuroblastoma
At the beginning of 2013, the newswires and social networks lit up with the news that a vaccine targeted to kill neuroblastoma cells had put a patient into remission. The case study was published in the high-impact journal “Pediatrics”. This work built on five years of pre-clinical research, resulting in some very promising new immunological targets for neuroblastoma. The project was ...
Ethical Issues for Control-Arm Patients …
A thought-provoking article that recently appeared online in the Journal of Clinical Oncology, ahead of full publication. The paper entitled, Ethical Issues for Control-Arm Patients After Revelation of Benefits of Experimental Therapy: A Framework Modeled in Neuroblastoma, discusses the decision to offer ch14.18 immunotherapy to control-arm patients on the Children’s Oncology Group (COG) clinical ...
Paladin Labs in licensing agreement for APN311 (ch14.18)
Paladin Labs Inc. have entered into an exclusive licensing agreement with Apeiron Biologics AG for APN311, the ch14.18 chimeric monoclonal antibody currently in a SIOPEN Phase III clinical trial across Europe. The license grants Paladin rights to market and sell APN311 in Canada and parts of Africa.
See the associated press release for further details.
Tübingen 2012 Neuroblastoma Symposium: from bench to bedside
Sincere appreciation is extended to NB Alliance UK for inviting me to attend this meeting and providing the travel funds.
This was the fourth meeting in a series on pediatric solid tumors and the first time the focus was on neuroblastoma. It was hosted at the Children’s Hospital (Kinderklinik) in the beautiful old city of Tübingen, which is home to the top ranked German University founded in ...
Pilot Study of Zoledronic Acid and Interleukin-2 for Refractory Pediatric Neuroblastoma
New phase I trial opening soon at University of Alabama, Birmingham
This trial will enroll 6 patients at 2 dose levels for IL2 given with fixed dose of zoledronic acid. Zoledronic acid will be given IV once every 3 weeks, and daily subcutaneous IL2 given weekdays for 2 weeks.
Patients must have evidence of disease and have not received prior antibody therapy with IL2.
See NIH listing for rationale:
To ...
Court rules in favor of UK child seeking antibody treatment
Randomization to ch14.18 alone challenged, UK court rules in favor of child
The SIOPEN trial now accruing in 20 countries in Europe randomizes children to the antibody ch14.18 alone or ch14.18 with subcutaneous IL2. Part of this trial was amended after the March 2009 release of the Children’s Oncology Group early results showing 2-year event free survival of 66% with ch14.18, IL2, and GM-CSF ...
AACR 2011: A new antibody approach for neuroblastoma?
Anti-ALK antibody explored at Children’s Hospital of Philadelphia
An increasingly important research topic in neuroblastoma focuses on anaplastic lymphoma kinase (ALK) mutation or expression. At AACR there were 8 presentations on ALK and NB. While efforts are ongoing to better target the ~7% of NB cases that have an ALK mutation, now there is also compelling research on the ALK protein expression ...
AACR 2011 ~ 102nd meeting
The American Association for Cancer Research (AACR) is the oldest and largest scientific organization in the world focused on every facet of cancer research. AACR was founded in 1907 by 11 physicians and scientists interested in research with the goal to “to further the investigation and spread the knowledge of cancer.” Since then, the AACR has grown to 33,000 members and publishes seven ...
New antibody trials in 2011
Antibodies for relapsed neuroblastoma
Given that recent studies such as COG-3973 [1] and others reveal that half or more of all children with high-risk neuroblastoma are refractory to induction or relapse, and that the majority worldwide never received antibodies as part of frontline treatment, there is currently a significant demand for access to antibody treatment after relapse.
Currently, the only ...
